Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYRO3 | Q06418 | 2/20 | 0.50 |
| ▸ | DYRK1B | Q9Y463 | 2/20 | 0.50 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.50 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.50 |
| ▸ | RET | P07949 | 2/20 | 0.50 |
| ▸ | PIM1 | P11309 | 2/20 | 0.50 |
| ▸ | KDR | P35968 | 2/20 | 0.50 |
| ▸ | GSK3A | P49840 | 2/20 | 0.50 |
| ▸ | GSK3B | P49841 | 2/20 | 0.50 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.50 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.50 |
| ▸ | MAP4K2 | Q12851 | 2/20 | 0.50 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.50 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.50 |
| ▸ | AURKA | O14965 | 1/20 | 0.50 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.50 |
| ▸ | JAK2 | O60674 | 1/20 | 0.50 |
| ▸ | PAK4 | O96013 | 1/20 | 0.50 |
| ▸ | ABL1 | P00519 | 1/20 | 0.50 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29388621 | 1.00 | TYRO3 (0.50) | TYRO3DYRK1BPRKD3MAP4K4RET | |
| Hydrochloric Acid SCHEMBL29487293 | 0.98 | TYRO3 (0.48) | TYRO3DYRK1BPRKD3MAP4K4RET | |
| SCHEMBL4849645 | 0.86 | PDE3B (0.45) | TYRO3DYRK1BPRKD3MAP4K4RET | |
| SCHEMBL2744269 | 0.83 | KDM4E (0.36) | — | |
| SCHEMBL30032670 | 0.75 | GDA (0.41) | TYRO3DYRK1BPRKD3MAP4K4RET | |
| SCHEMBL3726392 | 0.75 | GDA (0.41) | TYRO3DYRK1BPRKD3MAP4K4RET | |
| SCHEMBL2196062 | 0.75 | MAPK14 (0.36) | TYRO3DYRK1BPRKD3MAP4K4RET | |
| SCHEMBL30790289 | 0.74 | METAP2 (0.31) | — | |
| SCHEMBL5374927 | 0.74 | ALDH1A1 (0.50) | — | |
| SCHEMBL30031292 | 0.74 | ALDH1A1 (0.50) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 331 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240343733-A1 | COMPOUNDS FOR TARGETING DEGRADATION OF IRAK4 PROTEINS | C4 THERAPEUTICS, INC. | 2024-10-17 | — | — | US | claimed |
| EP-3801538-B1 | TLR7 AGONISTS | PRIMMUNE THERAPEUTICS INC (US) | 2024-10-02 | — | — | EP | claimed |
| EP-4367113-A1 | COMPOUNDS FOR TARGETING DEGRADATION OF IRAK4 PROTEINS | Biogen MA Inc. (US) | 2024-05-15 | — | — | EP | claimed |
| CN-117940414-A | Compounds for targeting IRAK4 protein degradation | 渤健马萨诸塞州股份有限公司 | 2024-04-26 | — | — | CN | claimed |
| EP-3281943-B1 | PROCESS FOR PRODUCING PURINONE DERIVATIVE | ONO PHARMACEUTICAL CO (JP) | 2023-06-28 | — | — | EP | claimed |
| EP-3590938-B1 | PURINONE DERIVATIVE AS BTK KINASE INHIBITOR | ONO PHARMACEUTICAL CO (JP) | 2023-05-24 | — | — | EP | claimed |
| WO-2023283610-A1 | COMPOUNDS FOR TARGETING DEGRADATION OF IRAK4 PROTEINS | BIOGEN MA INC. (US) | 2023-01-12 | — | — | WO | claimed |
| EP-3807278-B1 | PURINONE DERIVATIVES AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2022-08-31 | — | — | EP | claimed |
| WO-2022177302-A1 | PYRIMIDINE-FUSED RING COMPOUND WITH DNA-PK INHIBITION ACTIVITY AND USE THEREOF | 보령제약 주식회사 | 2022-08-25 | — | — | WO | claimed |
| US-20220241409-A1 | WATER SOLUBLE ADJUVANT AND COMPOSITION CONTAINING SAME | Sumitomo Pharma Co., Ltd. (JP) | 2022-08-04 | — | — | US | claimed |
| EP-2170274-A1 | COMPOSITIONS, ARTICLES AND METHODS COMPRISING TSPO LIGANDS FOR PREVENTING OR REDUCING TOBACCO-ASSOCIATED DAMAGE | Technion Research and Development Foundation, Ltd. (IL) | 2010-04-07 | — | — | EP | claimed |
| WO-2010018133-A1 | PURINE DERIVATIVES FOR USE IN THE TREATMENT OF ALLERGIC, INFLAMMATORY AND INFECTIOUS DISEASES | SMITHKLINE BEECHAM CORPORATION (US) | 2010-02-18 | — | — | WO | claimed |
| EP-2125792-A1 | PURINE DERIVATIVES AS IMMUNOMODULATORS | Smithkline Beecham Corporation (US) | 2009-12-02 | — | — | EP | claimed |
| EP-2121693-A1 | 8-OXOADENINE DERIVATIVES AS IMMUNO-MODULATORS | AstraZeneca AB (SE) | 2009-11-25 | — | — | EP | claimed |
| US-20090042890-A1 | Heteroaryl compounds, compositions thereof, and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC | 2009-02-12 | — | — | US | claimed |
| WO-2009004621-A1 | COMPOSITIONS, ARTICLES AND METHODS COMPRISING TSPO LIGANDS FOR PREVENTING OR REDUCING TOBACCO-ASSOCIATED DAMAGE | TECHNION RESEARCH & DEVELOPMENT FOUNDATION LTD. (IL) | 2009-01-08 | — | — | WO | claimed |
| US-20090005560-A1 | PRODUCTION METHOD OF DIAMINOPYRIMIDINE COMPOUNDS | AJINOMOTO CO. INC (JP) | 2009-01-01 | — | — | US | claimed |
| EP-2009003-A1 | Production method of diaminopyrimidine compounds | Ajinomoto Co., Inc. (JP) | 2008-12-31 | — | — | EP | claimed |
| WO-2008101867-A1 | PURINE DERIVATIVES AS IMMUNOMODULATORS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-08-28 | — | — | WO | claimed |
| WO-2008071976-A1 | 8-OXOADENINE DERIVATIVES AS IMMUNO-MODULATORS | ASTRAZENECA AB (SE) | 2008-06-19 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090005560-A1 | PRODUCTION METHOD OF DIAMINOPYRIMIDINE COMPOUNDS | DPYD, DHPS, UMPS | TYRO3 4297/4885DYRK1B 2842/4885PRKD3 1983/4885 |
| US-20220241409-A1 | WATER SOLUBLE ADJUVANT AND COMPOSITION CONTAINING SAME | TP53, MYD88, AQP1 | TYRO3 1449/4885DYRK1B 3818/4885PRKD3 2889/4885 |
| US-20240343733-A1 | COMPOUNDS FOR TARGETING DEGRADATION OF IRAK4 PROTEINS | IRAK4, IRAK2, IRAK1 | TYRO3 945/4885DYRK1B 1599/4885PRKD3 370/4885 |
| US-20090042890-A1 | Heteroaryl compounds, compositions thereof, and methods of treatment therewith | JAK2, CHEK2, SRC | TYRO3 141/4885DYRK1B 1866/4885PRKD3 129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.